Drug
Arformoterol Tartrate Inhalation
Arformoterol Tartrate Inhalation: highest development phase Phase 3, developed by Sumitomo Pharma. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Arformoterol tartrate inhalation solution NCT00250679 | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Arformoterol tartrate inhalation solution NCT00685841 | Phase 3 | COPD |
| Arformoterol tartrate inhalation solution NCT00691405 | Phase 2 | COPD |
Latest
No recent events.
Follow Arformoterol Tartrate Inhalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.